The possibility of using AR and miRNAs as markers to detect the presence of lymph node metastases also depends on the tumor subtype—a decrease in the level of AR expression can serve as a marker in HER2-positive subtypes, and a higher level of miR-205 expression and a decrease in miR-185 and miR-21 expression levels (compared with cases without metastases) may be a marker of metastasis in luminal B HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.